Overall, the Company is in a strong position having increased its current and total assets, compared to the previous quarter; eliminated the entire debt liability associated with debentures issued in Q4 2024 and Q1 2025 by converting all debentures into equity; maintained its ‘no going concern’ status; seen greater than $500,000 USD appreciation in the value of its cryptocurrency reserves as of date of filing; and seen its stock price almost tripled from $7.71 USD at Q1 close March 31, 2025 to $20.25 USD at Q2 close June 30, 2025. Management believes that there is sufficient cash on hand to maintain basic operations beyond March 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum Biopharma Reports Increased Liabilities in Latest Financial Statement
- Quantum BioPharma Reports Positive Phase 1 Results for MS Drug Lucid-MS
- Quantum Group subsidiary received CSR for Phase 1 MAD trial
- Quantum BioPharma Pursues Legal Action Over Alleged Stock Manipulation
- Quantum Group files reply, provides update on court case against CIBC, RBC